SCHEMBL19974842

SCHEMBL19974842

COc1ccccc1N(C=O)C(C)C(O)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
POLB P06746 2/20 0.38
IRAK4 Q9NWZ3 1/20 0.37
PAX8 Q06710 1/20 0.36
TLR9 Q9NR96 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975376 0.83 L3MBTL1 (0.40) KMT2AKDM4ELMNAPOLBPAX8
SCHEMBL21176264 0.82 HPGD (0.43) KMT2AKDM4ELMNACYP1A2POLB
SCHEMBL19974770 0.81 POLB (0.49) KMT2ASMN1; SMN2LMNACYP1A2POLB
SCHEMBL19974773 0.81 POLB (0.49) KMT2ASMN1; SMN2LMNACYP1A2POLB
SCHEMBL30062960 0.81 POLB (0.49) KMT2ASMN1; SMN2LMNACYP1A2POLB
SCHEMBL19975516 0.80 KMT2A (0.41) KMT2ASMN1; SMN2KDM4ELMNACYP1A2
SCHEMBL28316331 0.79 HPGD (0.40) KMT2ASMN1; SMN2KDM4ELMNACYP1A2
SCHEMBL28876091 0.78 ESR1 (0.41) KMT2ASMN1; SMN2KDM4ELMNACYP1A2
SCHEMBL30061792 0.77 KMT2A (0.47) KMT2ASMN1; SMN2KDM4EPOLBPAX8
SCHEMBL19974704 0.77 KMT2A (0.47) KMT2ASMN1; SMN2KDM4EPOLBPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885SMN1; SMN2 706/4885KDM4E 3330/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885SMN1; SMN2 1086/4885KDM4E 3784/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885SMN1; SMN2 706/4885KDM4E 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.